Oral Suspension Tedizolid Phosphate — Competitive Intelligence Brief

Oral Suspension Tedizolid Phosphate (Oral Suspension Tedizolid Phosphate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Oral Suspension Tedizolid Phosphate (Oral Suspension Tedizolid Phosphate) — Merck Sharp & Dohme LLC. Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Suspension Tedizolid Phosphate TARGET	Oral Suspension Tedizolid Phosphate	Merck Sharp & Dohme LLC	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin or placebo tablets	Azithromycin or placebo tablets	Rigshospitalet, Denmark	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

1. Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
2. University of Southern California · 2 drugs in this class
3. Arpida AG · 2 drugs in this class
4. Pfizer · 1 drug in this class
5. Shenzhen Third People's Hospital · 1 drug in this class
6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
7. Wuhan Pulmonary Hospital · 1 drug in this class
8. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class